CCR By the Numbers

Each year, CCR licenses new technologies, publishes articles in peer-reviewed journals, opens new clinical trials and brings in thousands of patients and trainees. Take a look at our year as told by the numbers.

  • ~1500Articles in peer-reviewed journals
  • ~1000Trainees
  • 70New Employee Invention Reports
  • 57Issued U.S. patents
  • 655Active licenses
  • 183Active Cooperative Research and Development Agreements (CRADAs)
  • 245Clinical trials
  • 1403New patients
  • 58New trials opening

CCR Products:

Vaccines and Therapeutics

  • 2-F-Ara-Fludara, Berlex
  • Videx®, Berlex
  • Hivid®, BMS
  • Paclitaxel®, BMS
  • Trimetrexate- Neu Trexin, US Bioscience
  • Zenapax®, Hoffman La Roche
  • Vitravene®, Isis Pharma
  • Zevalin®, IDEC Pharma
  • Kepivance®, Amgen
  • Gardasil®, Merck
  • Prezista®, Tibotec Pharma
  • Cervarix®, GSK
  • Lumoxiti®, Innate Pharma
  • *Avelumab, Pfizer
  • *Istodax®, Celgene
  • *Voraxaze®, BTG
  • *Avastin®, Genentech
  • *YescartaTM, Kite Pharma
  • *Selumetinib, AstraZeneca
  • *POMALYST®, Bristol Myers Squibb
  • *CCR clinical trial testing


  • Diagnostic test for HIV-1
  • Diagnostic test for HTLV-1
  • DNA Probe for Breast Cancer
  • Multi-Replica Blotting Kit for Proteins


  • Laser Capture Microdissection
  • UroNav


*denotes CCR clinical trial testing